Predictmedix AI Announces Non-Brokered Private Placement

Executive Summary

• Predictmedix AI Inc. announced a proposed non‑brokered private placement of up to 18 million units at C$0.05 per unit, targeting gross proceeds of up to C$900,000.
• Each unit consists of one common share and half of a warrant allowing purchase of an additional half share at C$0.15 for 36 months; warrants may be accelerated if the CSE price exceeds C$0.30 for ten consecutive trading days after four months post‑closing.
• Proceeds are earmarked to strengthen core AI technology, advance product verticals (clinical trial applications, SmartHealth certification, B2C vital‑scanning platform), and support corporate functions such as regulatory compliance and investor relations.

Key Details

• Offering Size: Up to 18,000,000 units
• Unit Price: C$0.05 per unit
• Maximum Gross Proceeds: C$900,000
• Composition of Each Unit:
• 1 common share of Predictmedix AI Inc.
• ½ of one common‑share purchase warrant (entitles holder to buy ½ share at C$0.15)
• Warrant Terms:
• Exercise price: C$0.15 per share
• Expiration: 36 months after the closing date of the offering
• Acceleration clause: If, after four months + 1 day post‑closing, the volume‑weighted average price on the CSE is ≥ C$0.30 for any ten consecutive trading days, the company may accelerate warrant expiry to 30 days after written notice.
• Use of Proceeds:
• Strengthen core AI technology platform (Predictmedix Core AI Engine)
• Support growth verticals: AI‑powered clinical trial applications, SmartHealth AI Station certification initiatives, B2C vital‑scanning mobile platform development
• Maintain and enhance corporate functions (public‑company operations, regulatory compliance, investor engagement)
• Strategic Context: Recent participation in the 25th MK Investment Conference in Munich generated strong investor interest, reinforcing confidence in the company’s AI‑driven healthcare approach.

Notable Quotes

“The investor engagement and strategic discussions in Munich validated the global relevance of our AI technology,” said Dr. Rahul Kushwah, COO of Predictmedix Inc. “This financing provides additional flexibility as we continue to strengthen our platform, explore new partnerships, and scale commercialization opportunities.”